Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.

Postgraduate Medicine
Kristina JohnssonS Parikh

Abstract

Dapagliflozin reduces hyperglycemia in type 2 diabetes mellitus (T2DM) and lowers blood pressure, at least in part, secondary to mild diuresis consequent to dapagliflozin-induced glucosuria. While blood-pressure lowering may contribute to cardiovascular risk reduction, dapagliflozin-induced diuresis may potentially contribute to adverse events (AEs) of volume reduction. The present analysis compared the frequency of AEs of volume reduction between dapagliflozin and placebo. Pooled data were assessed from 13 placebo-controlled dapagliflozin clinical trials ≤24 weeks in patients with T2DM, overall, and in those at risk (aged ≥65y, estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m(2), or on antihypertensive therapy). Longer-term (≤104 weeks) data were available for 9 of these trials. The frequency of patients experiencing ≥1 AE of volume reduction over 24 weeks was low overall; 27/2360 (1.1%) with dapagliflozin 10 mg and 17/2295 (0.7%) with placebo; and slightly more frequent in patients ≥65 years (11/665 [1.7%] and 6/711 [0.8%], respectively) and in patients receiving loop diuretics (6/236 [2.5%] and 4/267 [1.5%], respectively). Over 104 weeks, AEs of volume reduction occurred in 38/2026 (1.9%) with dapagliflozin 10 m...Continue Reading

References

Oct 2, 2007·The American Journal of Medicine·Vishal Gupta, Lewis A Lipsitz
Dec 31, 2008·Diabetes Care·James F ListFred T Fiedorek
Mar 21, 2012·Annals of Internal Medicine·John P H WildingUNKNOWN Dapagliflozin 006 Study Group
Jan 4, 2013·Diabetes Care·UNKNOWN American Diabetes Association
May 15, 2013·Diabetes, Obesity & Metabolism·H J Lambers HeerspinkJ List
May 6, 2015·Therapeutic Advances in Endocrinology and Metabolism·Deborah Hinnen
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Feb 21, 2016·Cardiovascular Diabetology·Christian SonessonIngrid Gause-Nilsson

❮ Previous
Next ❯

Citations

Oct 28, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Genjiro Kimura
Nov 8, 2016·Expert Opinion on Drug Metabolism & Toxicology·Vasilios TsimihodimosMoses S Elisaf
Jun 8, 2018·Circulation Journal : Official Journal of the Japanese Circulation Society·Takahiro Okumura, Toyoaki Murohara
Aug 14, 2019·Expert Opinion on Investigational Drugs·Ernest AdeghateErnest A Adeghate
Nov 5, 2017·Drug Safety - Case Reports·Georg GelbeneggerMichael Schwameis
Oct 12, 2018·Archives of Endocrinology and Metabolism·Julio RosenstockGabriela Luporini Saraiva
Mar 23, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Andrew McGovernSimon de Lusignan
Apr 3, 2020·Drugs & Aging·Joaquim Silva CustódioJoão Eduardo Nunes Salles

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
Agata PtaszynskaJames F List
Journal of the American Society of Hypertension : JASH
Raymond V Oliva, George Bakris
© 2022 Meta ULC. All rights reserved